Mutations of SLC19A3 in humans cause severe neurometabolic disorders in the form of Wernicke’s-like encephalopathy (WLE)14 and biotin- and thiamine-responsive basal ganglia disease (BTBGD)15–17. Here, SLC19A3 is linked to biotin-responsive basal ganglia disease.